Comments
Vaccine-maker Biological E Ltd (BE) has successfully completed the phase II/III study of vero cell-based Japanese encephalitis (JE) vaccine.
The inactivated vaccine was manufactured in India by BE based on the technology transfer agreement with Intercell.
“`We are excited about the successful completion of our phase-II/III clinical study which enables us to offer this novel and safe vaccine to combat JE not only in India but also across Asia,” Dr Vijay Kumar Datla, Chairman and Managing Director of Biological E said in a press release on Friday.
The vaccine was not produced in mouse brains, but in-vitro using cell culture hence there is reduced risk of rare autoimmune neurological complications, the Hyderabad-based company said.
The results of the study would be submitted to the Indian regulatory authority for licensure.
JE is the leading cause of viral encephalitis in Asia, with 30,000–50,000 cases reported each year
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.